登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
ClinicalTrials.gov 上登记的一项胃癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06500052,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
The pathologic histology and/or cytology diagnosis of locally advanced or metastatic positive HER2 / low expression of the digestive tract tumor and other solid tumor;
入选标准第 5 条
Age: ≥18 years old and ≤75 years old (stage Ia); ≥18 years old (stage Ib);
入选标准第 3 条
Toxicity of previous antineoplastic therapy has returned to ≤ grade 1 defined by NCI-CTCAE v5.0;
入选标准第 9 条
For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, serum pregnancy must be negative, and must be non-lactating; All the patients (no matter male or female) shall be 6 months after the end of the treatment period and full barrier precautions.
入选标准第 14 条
ECOG 0 or 1;
入选标准第 8 条
Must have at least one measurable lesion according to RECIST v1.1 definition;
入选标准第 7 条
Other malignant tumors diagnosed within 5 years before the first dose;
排除标准第 5 条
HIV antibody positive, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;
排除标准第 16 条
Pregnant or lactating women;
排除标准第 19 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:化验:血常规、肝肾功能。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06500052,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Voluntarily sign the informed consent and follow the requirements of the protocol; No gender limit; Age: ≥18 years old and ≤75 years old (stage Ia); ≥18 years old (stage Ib); Expected survival time ≥3 months; The pathologic histology and/or cytology diagnosis of locally advanced or metastatic positive HER2 / low expression of the digestive tract tumor and other solid tumor; Consent to provide archival tumor tissue samples or fresh tissue samples from primary or metastatic lesions within 2 years; Must have at least one measurable lesion according to RECIST v1.1 definition; ECOG 0 or 1; Toxicity of previous antineoplastic therapy has returned to ≤ grade 1 defined by NCI-CTCAE v5.0; No severe cardiac dysfunction, left ventricular ejection fraction ≥50%; Organ function level must meet the requirements; Coagulation function: international normalized ratio ≤1.5, and activated partial thromboplastin time ≤1.5ULN; Urine protein ≤2+ or ≤1000mg/24h; For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, serum pregnancy must be negative, and must be non-lactating; All the patients (no matter male or female) shall be 6 months after the end of the treatment period and full barrier precautions.排除标准:Exclusion Criteria:
Anti-tumor therapy such as chemotherapy or biological therapy has been used within 4 weeks or 5 half-lives before the first dose; Mitomycin and nitrosoureas were administered within 6 weeks before the first dose; Oral drugs such as fluorouracil; History of severe heart disease; QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia; Active autoimmune and inflammatory diseases; Other malignant tumors diagnosed within 5 years before the first dose; Hypertension poorly controlled by two antihypertensive drugs; Patients with poor glycemic control before the first dose; Have to hormone treatment of interstitial lung disease, or the current with ILD or suspected suffering from such diseases; Complicated pulmonary diseases leading to clinically severe respiratory function impairment; Patients with massive or symptomatic effusions or poorly controlled effusions; Imaging examination showed that the tumor had invaded or wrapped around the chest, neck, pharynx and other large blood vessels; Screening for unstable thrombotic events requiring therapeutic intervention within the preceding 6 months; Patients with active central nervous system metastases; Patients with a history of allergy to recombinant humanized antibody or human-mouse chimeric antibody or to any of the excipients of BL-M17D1; Prior organ transplantation or allogeneic hematopoietic stem cell transplantation; HIV antibody positive, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection; Active infection requiring systemic therapy with serious infection within 4 weeks before informed consent; There were indications of pulmonary infection or active pulmonary inflammation within 2 weeks before informed consent; Participated in another clinical trial within 4 weeks before the first dose; Pregnant or lactating women; Patients with superior vena cava syndrome should not be rehydrated; A history of severe neurological or psychiatric illness; Severe unhealed wound, ulcer, or fracture within 4 weeks before signing the informed consent; Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent; History of intestinal obstruction, inflammatory bowel disease, or extensive bowel resection or presence of Crohn's disease, ulcerative colitis, or chronic disease Sexual diarrhea; Patients scheduled for vaccination or receiving live vaccine within 28 days before the first dose; Other conditions for participation in the trial were not considered appropriate by the investigator.
引自 ClinicalTrials.gov, NCT06500052, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06500052,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。